Rising Giants: Major Players Drive Exosome Market Innovation, Redefining Diagnostics and Therapy

The Exosome Diagnostic And Therapeutic Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Exosome Diagnostic And Therapeutic Market:
https://www.thebusinessresearchcompany.com/report/exosome-diagnostic-and-therapeutic-global-market-report

According to The Business Research Company’s Exosome Diagnostic And Therapeutic Global Market Report 2024, The exosome diagnostic and therapeutic market size has grown exponentially in recent years. It will grow from $0.36 billion in 2023 to $0.48 billion in 2024 at a compound annual growth rate (CAGR) of 31.1%.  The  growth in the historic period can be attributed to biological research advancements, emergence of precision medicine, biomedical imaging innovations, cancer research and oncology, healthcare industry investments.

The exosome diagnostic and therapeutic market size is expected to see exponential growth in the next few years. It will grow to $1.28 billion in 2028 at a compound annual growth rate (CAGR) of 28.1%.  The growth in the forecast period can be attributed to growing clinical applications, integration with digital health technologies, supportive regulatory environment, gene editing and rna therapeutics, expanded role in immuno-oncology. Major trends in the forecast period include exosome-based drug discovery, biomimetic exosome engineering, commercialization of exosome products, exosome-loaded therapeutic cargo, liquid biopsy for cancer screening.

The rising prevalence of chronic diseases is expected to propel the growth of the exosome diagnostic and therapeutic market going forward. Chronic disease is a form of illness that lasts three months or more and can deteriorate with time. Diagnostic and therapeutic applications of exosomes act as possible biomarkers in cancer that provide more sensitive disease monitoring, making personalized medicine more reachable. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, there will be 142.66 million people with chronic diseases worldwide by the year 2050. Therefore, the rising prevalence of chronic diseases is driving the exosome diagnostics and therapeutics market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12346&type=smp

The exosome diagnostic and therapeutic market covered in this report is segmented –
1) By Product: Instruments, Software, Reagents And Kits
2) By Application: Diagnostics, Therapeutic
3) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Hospitals And Clinics, Other End Users

Major companies operating in the exosome diagnostic and therapeutic market are developing innovative products, such as sample purification systems, to meet larger customer bases, increase sales, and increase revenue. A sample purification system is a set of processes and technologies designed to remove impurities and contaminants from a sample, such as DNA, RNA, proteins, or other biomolecules. For instance, in February 2023, Biological Dynamics Inc., a US-based biotechnology company, launched ExoVerita, an exosome-isolation platform for early disease surveillance and other applications. The ExoVita Pancreas assay detects particular exosomal protein indicators and has been shown to detect Stage 1 and Stage 2 pancreatic ductal adenoma carcinoma (PDAC) using blood-based exosome samples enriched on the patented ExoVerita apparatus. The company will use this validation to test samples from the ExoLuminate registry trial (NCT05625529), which has started actively recruiting patients with high-risk PDAC to examine the test’s clinical value. Patients with clinical signs such as pancreatitis or known pancreatic lesions, individuals with a genetic or familial propensity, and newly diagnosed diabetics over 50 are also eligible.

The exosome diagnostic and therapeutic market report table of contents includes:

1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model